Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Autonomix Medical, Inc.

Ticker
AMIX
Sector
Industry
Report date
November 10, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent developments highlight Autonomix Medical's progress in regulatory interactions, patent portfolio expansion, clinical data presentation, and capital raising activities.

Recent developments:
  • Autonomix Medical completed an FDA pre-submission meeting on its standalone transvascular sensing platform, advancing its regulatory strategy for initial U.S. clearance [N1].
  • The company received a European patent for its neural activity assessment technology, strengthening its intellectual property portfolio [N2].
  • Autonomix secured a broad U.S. patent to expand its precision neuromodulation platform, enhancing its technology protection [N4].
  • Clinical data demonstrating rapid and durable pain relief across all stages of pancreatic cancer were showcased at the 2026 ASCO Gastrointestinal Cancers Symposium [N6].
  • The company entered a $4.9 million warrant exercise inducement deal, indicating capital raising efforts [N3].
Overview

Autonomix Medical, Inc. develops a catheter-based sensing technology platform aimed at nerve-targeted medical procedures. The platform combines a sensing antenna array and microchip to acquire low-amplitude biological electrical signals through blood vessel walls, amplifying and processing these signals to support clinical decision-making and nerve-targeted treatment guidance. The company’s staged strategy involves sensing neural activity, treating targeted nerves, and verifying treatment effectiveness. Autonomix has prioritized a standalone transvascular sensing system as its initial U.S. regulatory and commercialization focus, targeting FDA 510(k) clearance for general sensing functionality. This approach offers a potentially earlier and less capital-intensive regulatory pathway compared to combined sensing and ablation therapies requiring de novo clearance. The company has demonstrated proof-of-concept in human clinical studies for pancreatic cancer pain management and is advancing signal interpretation methods to support future applications in cardiovascular and peripheral nervous system conditions. Autonomix holds multiple patents protecting its neuromodulation and neural activity assessment technologies and is actively engaged in clinical development and regulatory interactions.

Executive summary

Autonomix Medical, Inc. is a development-stage medical device company focused on nerve-targeted procedures using a catheter-based sensing platform designed to acquire and interpret neural signals for clinical decision-making and treatment guidance. The company prioritizes a standalone transvascular sensing system targeting FDA 510(k) clearance as an initial regulatory and commercialization step. It has demonstrated proof-of-concept in human clinical studies for pancreatic cancer pain management and holds multiple U.S. and European patents expanding its neuromodulation technology portfolio. As of September 30, 2026, Autonomix reported no revenue, a net loss of $3.126 million, and maintained strong liquidity with $7.692 million in cash and equivalents and a current ratio of 6.52. The company faces regulatory and technical risks related to FDA clearance pathways, signal acquisition and interpretation challenges, and potential Nasdaq listing compliance risks. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for AMIX

Bull case model:

Autonomix Medical’s technology platform addresses a novel and challenging area of nerve-targeted sensing and treatment with potential applications in pain management and cardiovascular conditions. The company’s strategy to pursue an initial FDA 510(k) clearance for a standalone sensing device may enable earlier market entry with lower capital requirements compared to combined therapy devices. Its expanding patent portfolio and clinical proof-of-concept data provide a foundation for future product development and regulatory submissions. Successful regulatory clearance and commercialization of the sensing platform could establish a new clinical tool for neural signal acquisition and treatment guidance, potentially enabling subsequent therapeutic applications and expanded indications.

Bear case model:

The company faces significant regulatory risks, including the possibility that FDA clearance may be limited to general sensing functionality without authorization for therapeutic ablation or advanced clinical claims, requiring additional costly and time-consuming submissions. Technical challenges in reliably acquiring and interpreting neural signals may limit the clinical utility and commercial viability of its products. As a development-stage company with no revenue and ongoing net losses, Autonomix depends on capital raising and maintaining Nasdaq listing compliance, with risks of delisting if market value thresholds are not met. Delays or failures in regulatory approval, clinical validation, or commercialization could materially adversely affect its business prospects.

Moat:

Autonomix Medical’s moat is primarily based on its proprietary catheter-based sensing technology platform that uniquely acquires and amplifies low-amplitude neural signals through blood vessel walls, combined with its signal processing capabilities. The company’s extensive patent portfolio, including broad U.S. and European patents covering neural activity assessment and neuromodulation technologies, provides intellectual property protection. Its clinical proof-of-concept data in pancreatic cancer pain management and ongoing regulatory engagement with the FDA support its technological differentiation. The specialized nature of its technology, combined with regulatory barriers and the complexity of neural signal acquisition and interpretation, creates entry challenges for competitors. However, as a development-stage company without commercial products or revenue, its moat depends on successful regulatory clearance, clinical validation, and commercialization execution.

Risks overview
Risks summary
The most significant risks involve regulatory uncertainties regarding FDA clearance scope and timing, technical challenges in neural signal acquisition and interpretation, and financial risks related to ongoing losses and Nasdaq listing compliance.
Risks details:

• Regulatory Approval Risks: FDA feedback from pre-submission meetings is nonbinding; additional testing, clinical data, or different regulatory pathways may be required, causing delays or increased costs. Initial clearance may be limited to sensing functionality without therapeutic claims.
• Technical and Validation Risks: Challenges exist in reliably acquiring and interpreting neural signals due to physiological and procedural variables, which may limit clinical utility and require technology modifications or discontinuation of programs.
• Financial and Liquidity Risks: The company has no revenue and reports net losses, relying on capital raising activities. Maintaining Nasdaq listing compliance is uncertain, with risk of delisting if market value falls below required thresholds.

FINAL FORECAST FOR AMIX

Final take one line
Autonomix Medical, Inc. exhibits very high visibility with detailed disclosures on its nerve-targeted sensing technology, regulatory progress, patent portfolio, clinical data, and financial position, alongside clear regulatory and technical risks.
Final take 12 to 24 month view

Business trends: Focus on standalone transvascular sensing system targeting FDA 510(k) clearance, expanding patent portfolio, and advancing clinical validation in nerve-targeted therapies.
Execution milestones: Completion of FDA pre-submission meetings, securing U.S. and European patents, presentation of clinical data at major symposia, and capital raising through warrant inducements.
Key risks: Regulatory uncertainties on clearance scope and timing, technical challenges in neural signal acquisition and interpretation, and financial risks including Nasdaq listing compliance and ongoing net losses.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • Autonomix Medical, Inc. is a development-stage medical device company focused on nerve-targeted procedures using a catheter-based sensing antenna array and microchip technology to acquire and amplify low-amplitude biological electrical signals through blood vessel walls for clinical decision-making and treatment guidance [S2].
  • The company’s technology platform is designed to support interpretation of recorded neural signals and guidance and verification of nerve-targeted treatment, with a staged strategy described as 'sense, treat and verify' [S2].
  • Autonomix has prioritized a standalone transvascular sensing system as its initial U.S. regulatory and commercialization opportunity, targeting FDA 510(k) clearance for general sensing functionality [S2].
  • The standalone sensing device aims to provide an earlier and less capital-intensive regulatory pathway compared to combined sensing and ablation therapy, which requires de novo clearance and pivotal clinical trials [S2].
  • The company has conducted human clinical studies demonstrating proof-of-concept for treating targeted nerves with a commercial RF ablation system in pancreatic cancer pain management [S2].
  • Autonomix is advancing understanding of recorded signals and developing processing methods to provide physicians with physiological information before, during, and after interventions, positioning the platform for future cardiovascular and peripheral nervous system applications [S2].
  • The company holds multiple patents, including a broad U.S. patent to expand its precision neuromodulation platform and European patents for neural activity assessment and catheter-based neuromodulation technologies [N2][N4].
  • Recent clinical data showcased rapid and durable pain relief across all disease stages of pancreatic cancer, presented at the 2026 ASCO Gastrointestinal Cancers Symposium [N6].
  • Autonomix has entered warrant exercise inducement deals totaling several million dollars, indicating capital raising activities [N3].
  • The company reported a net loss of $3.126 million for the quarter ended September 30, 2026, with no revenue recognized during that period [S2].
  • As of September 30, 2026, Autonomix had $7.692 million in cash and equivalents, current assets of $8.176 million, current liabilities of $1.254 million, resulting in a current ratio of 6.52 and a cash ratio of 6.13, indicating strong liquidity [S2].
  • The company’s common stock is listed on Nasdaq under the ticker AMIX, with approximately 11.4 million shares outstanding as of June 10, 2026 [S1].
  • Management includes CEO Brad Hauser (appointed June 2024), Chief Medical Officer Dr. Robert Schwartz (co-founder), CTO Landy Toth (founder and key inventor), CFO Trent Smith (joined July 2023), and Executive Chairman Walter V. Klemp (joined January 2022) [S1].
  • The company faces regulatory risks including the possibility that FDA feedback from pre-submission meetings is nonbinding and that additional testing, clinical data, or different regulatory pathways may be required, potentially causing delays or increased costs [S2].
  • Initial FDA clearance may be limited to general sensing functionality and may not cover therapeutic ablation, neural signal interpretation for clinical decision-making, procedural guidance, or treatment verification, requiring further regulatory submissions [S2].
  • Technical challenges exist in reliably acquiring and interpreting neural signals from within blood vessels, with physiological and procedural variables potentially affecting signal quality and clinical significance [S2].
  • The company’s ability to meet safety, efficacy, and performance criteria for regulatory approval and commercial viability is uncertain, with risks of delays, increased costs, or failure to commercialize some or all products [S2].
  • There is a risk of Nasdaq delisting if the company’s market value of listed securities falls below $5 million for 30 consecutive business days, which could reduce liquidity and market price [S2].
Sources
Sources - Context summary

Generated 2026-11-10

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-06-15 | 10-K/A
  • S2 | 2026-11-10 | 10-Q
Sources - News headlines
  • N1 | 2026-09-30 | www.nasdaq.com | Autonomix Medical Completes FDA Pre-Submission Meeting On Standalone Transvascular Sensing Platform | https://www.nasdaq.com/articles/autonomix-medical-completes-fda-pre-submission-meeting-standalone-transvascular-sensing
  • N2 | 2026-09-24 | www.nasdaq.com | Autonomix Medical Receives European Patent For Neural Activity Assessment Technology | https://www.nasdaq.com/articles/autonomix-medical-receives-european-patent-neural-activity-assessment-technology
  • N3 | 2026-08-25 | www.nasdaq.com | Autonomix Enters $4.9 Mln Warrant Exercise Inducement Deal; Shares Jump | https://www.nasdaq.com/articles/autonomix-enters-49-mln-warrant-exercise-inducement-deal-shares-jump
  • N4 | 2026-08-05 | www.nasdaq.com | Autonomix Secures Broad U.S. Patent To Expand Precision Neuromodulation Platform | https://www.nasdaq.com/articles/autonomix-secures-broad-us-patent-expand-precision-neuromodulation-platform
  • N5 | 2026-07-30 | www.nasdaq.com | Top Biotech Gainers: SPRC On Watch, AVTR, NEO Boost Full-Year Outlook, SMTI Scooped Up | https://www.nasdaq.com/articles/top-biotech-gainers-sprc-watch-avtr-neo-boost-full-year-outlook-smti-scooped
  • N6 | 2026-01-09 | www.globenewswire.com | Autonomix Showcases Compelling PoC Study Clinical Data Showing Rapid and Durable Pain Relief Across All Disease Stages of Pancreatic Cancer at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium | https://www.globenewswire.com/news-release/2026/01/09/3216092/0/en/Autonomix-Showcases-Compelling-PoC-Study-Clinical-Data-Showing-Rapid-and-Durable-Pain-Relief-Across-All-Disease-Stages-of-Pancreatic-Cancer-at-the-2026-ASCO-Gastrointestinal-GI-Can.html
  • N7 | 2025-05-01 | www.nasdaq.com | Autonomix Medical, Inc. Announces Successful Initial Trial Phase and Plans for Market Expansion Study in Pancreatic Cancer Pain Management | https://www.nasdaq.com/articles/autonomix-medical-inc-announces-successful-initial-trial-phase-and-plans-market-expansion
  • N8 | 2025-04-30 | www.nasdaq.com | Autonomix Medical Reports Successful Phase 1 Trial Results for Pain Management in Pancreatic Cancer, Initiates Phase 2 Study | https://www.nasdaq.com/articles/autonomix-medical-reports-successful-phase-1-trial-results-pain-management-pancreatic
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine